Replies to post #166992 on Amarin Corp Plc (AMRN)

[couldbebetter]

A price increase or not for Vascepa may have to consider many factors
such as the future pricing of Vascepa in foreign markets such as Canada
(which will demand a discounted price.) AMRN should have a long-term
pricing strategy which considers all future factors. Amgen has already
lowered the price of Repatha (a PCKS-9) to around $2500. Given that
Vascepa is far more effective (and a patient could have both) one has
to wonder if that will be a common practice in the future. ( I think
Kiwi is on both Repatha and Vascepa.) Then, there is Adam Feuersein
who suggested that AMRN should be acquired by Amgen. I bring this up
here because I wonder if Amgen views Vascepa as a "threat" or as the
better drug of the two. If you are Amgen, how do you compete against
all of the other PCKS-9's and how do you deal with Vascepa (a much
superior medication.) One could argue that most patients on a PCKS-9
should also be on Vascepa. I read that the reason why Amgen cut its
price on Repatha was because of the other PCKS-9's. Is that the reason
or did they cut it to be priced lower than Vascepa? What is interesting
is that the combined price of Repatha and Vascepa are now less than half
the price of what Repatha was priced at initially. I also wonder why
Adam Feuerstein used Amgen as his example for why AMRN should be sold.
Did AF just pull it out of his ***, or does he have some other reason
to suggest such a tie-up?

[jessellivermore]

jt00....

Quote: "One thing nobody has mentioned on here (very surprising) and I think would be a MAJOR positive for shareholders is a V price increase."

Couldn't disagree with you more...I'm going with the soon to be CEO of the year JT....

Definitely volume over price is the key strategy...Every cent off the price as long as Amarin shows a healthy profit strengthens our position with the insurers and weakens our potential generic competitors.. Monopoly Strategy 101...Right now the key is the number of scripts and your proposal is a killer.

Rising script numbers will be a big catalyst...Before 9/24/2018..I pretty much ignored the weekly script counts...because they really did not mean squat...Now they are huge...even though they are going to increase slowly for awhile..

IMO..The next big event is going to be FDA's announcement of a priority review...That may take till spring time, but it might come a lot sooner..Vascepa meets the necessary criteria..Life saving and a huge indication...

Patience everyone...

":>) JL

[sts66]

They already raised the price by 6% for 2019 - haven't announced it, but when you compare copays on Medicare.gov for 2018 vs. 2019 for the same plan it's clear as day. Raising prices by any larger amount in 2019 would be suicide - on T4 V is already expensive, making copays higher would lead to much less use because people just can't afford it. AMRN makes plenty of money with current pricing, no need to be greedy - just grow sales volumes and profits will roll in - well, after R-IT is approved and formularies change.